PHAXIAM Therapeutics S.A. (0QSS.L)

EUR 1.76

(1.03%)

Total Liabilities Summary of PHAXIAM Therapeutics S.A.

  • PHAXIAM Therapeutics S.A.'s latest annual total liabilities in 2023 was 25.69 Million EUR , up 15.1% from previous year.
  • PHAXIAM Therapeutics S.A.'s latest quarterly total liabilities in 2024 Q2 was 23.66 Million EUR , up 192.38% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported annual total liabilities of 22.32 Million EUR in 2022, down -49.17% from previous year.
  • PHAXIAM Therapeutics S.A. reported annual total liabilities of 43.92 Million EUR in 2021, down -18.45% from previous year.
  • PHAXIAM Therapeutics S.A. reported quarterly total liabilities of 23.66 Million EUR for 2024 Q2, up 192.38% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported quarterly total liabilities of 28.89 Million EUR for 2023 Q1, up 29.45% from previous quarter.

Annual Total Liabilities Chart of PHAXIAM Therapeutics S.A. (2023 - 2012)

Historical Annual Total Liabilities of PHAXIAM Therapeutics S.A. (2023 - 2012)

Year Total Liabilities Total Liabilities Growth
2023 25.69 Million EUR 15.1%
2022 22.32 Million EUR -49.17%
2021 43.92 Million EUR -18.45%
2020 53.86 Million EUR 63.29%
2019 32.98 Million EUR 48.33%
2018 22.23 Million EUR 60.66%
2017 13.84 Million EUR 48.38%
2016 9.32 Million EUR 58.87%
2015 5.87 Million EUR 22.77%
2014 4.78 Million EUR 9.64%
2013 4.36 Million EUR -69.22%
2012 14.17 Million EUR 0.0%

Peer Total Liabilities Comparison of PHAXIAM Therapeutics S.A.

Name Total Liabilities Total Liabilities Difference
Boiron SA 198.7 Million EUR 87.069%
Laboratorios Farmaceuticos Rovi, S.A. 256.39 Million EUR 89.978%
Vetoquinol SA 165.12 Million EUR 84.439%
Valneva SE 341.14 Million EUR 92.468%
AB Science S.A. 46.5 Million EUR 44.751%
Nanobiotix S.A. 95.74 Million EUR 73.162%
Vivoryon Therapeutics N.V. 4.54 Million EUR -465.098%
BioSenic S.A. 32.26 Million EUR 20.36%
ABIVAX Société Anonyme 131.05 Million EUR 80.393%
Formycon AG 387.61 Million EUR 93.371%